Sven Stegemann, director of pharmaceutical business development, Lonza Pharma & Biotech, discusses how using sprinkle formulation technology helps manufacturers focus on the patient in medicine development.
medicines
In the past 20 years, advancements such as human genome sequencing and drug products like Herceptin which target gene-derived breast cancer have opened up a new scientific horizon to understand diseases’ root causes and to identify clinical targets and their respective treatments.